D.A. Davidson & CO. Sells 952 Shares of Zoetis Inc. $ZTS

D.A. Davidson & CO. cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,143 shares of the company’s stock after selling 952 shares during the quarter. D.A. Davidson & CO.’s holdings in Zoetis were worth $3,453,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Nova Wealth Management Inc. acquired a new position in Zoetis during the 1st quarter worth about $25,000. 1248 Management LLC acquired a new position in Zoetis during the 1st quarter worth about $27,000. Saudi Central Bank acquired a new position in Zoetis during the 1st quarter worth about $29,000. REAP Financial Group LLC lifted its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares in the last quarter. Finally, Cornerstone Planning Group LLC lifted its position in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ZTS. UBS Group reduced their price target on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Friday. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $195.00.

Zoetis Price Performance

Shares of ZTS opened at $146.14 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a 50 day simple moving average of $148.18 and a 200 day simple moving average of $153.50. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $184.40. The firm has a market capitalization of $64.77 billion, a PE ratio of 25.15, a P/E/G ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the firm posted $1.56 EPS. The business’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.